Skip to content
Products & Services · Net revenues

Linzess — Net revenues

AbbVie Linzess — Net revenues increased by 61.7% to $283M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 91.2%, from $148M to $283M. Over 4 years (FY 2021 to FY 2025), Linzess — Net revenues shows a downward trend with a -3.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2018
Last reportedQ1 2026May 8, 2026
Rolls up toTotal Revenue

How to read this metric

An increase indicates strong market adoption and effective commercial execution for this therapeutic, while a decrease may signal increased competition, patent expiration, or shifts in prescribing patterns.

Detailed definition

This metric represents the total net sales generated by the Linzess/Constella product line, a key gastrointestinal thera...

Peer comparison

Comparable to product-level revenue reporting for specific blockbuster drugs or therapeutic franchises within other large-cap pharmaceutical companies.

Metric ID: abbv_segment_linzess_constella_net_revenues

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$268M$261M$287M$240M$255M$271M$269M$259M$278M$288M$283M$266M$221M$234M$233M$148M$258M$326M$175M$283M
QoQ Change-2.6%+10.0%-16.4%+6.3%+6.3%-0.7%-3.7%+7.3%+3.6%-1.7%-6.0%-16.9%+5.9%-0.4%-36.5%+74.3%+26.4%-46.3%+61.7%
YoY Change-4.9%+3.8%-6.3%+7.9%+9.0%+6.3%+5.2%+2.7%-20.5%-18.8%-17.7%-44.4%+16.7%+39.3%-24.9%+91.2%
Range$148M$326M
CAGR+1.2%
Avg YoY Growth+2.8%
Median YoY Growth+3.3%

Frequently Asked Questions

What is AbbVie's linzess — net revenues?
AbbVie (ABBV) reported linzess — net revenues of $283M in Q1 2026.
How has AbbVie's linzess — net revenues changed year-over-year?
AbbVie's linzess — net revenues increased by 91.2% year-over-year, from $148M to $283M.
What is the long-term trend for AbbVie's linzess — net revenues?
Over 4 years (2021 to 2025), AbbVie's linzess — net revenues has grown at a -3.3% compound annual growth rate (CAGR), from $1.04B to $907M.
What does linzess — net revenues mean?
The total net revenue generated from the sale of the Linzess/Constella pharmaceutical product line.